Bradley Lerman - Medtronic PLC President
| MDT Stock | USD 79.19 0.11 0.14% |
President
Mr. Bradley E. Lerman is Senior Vice President, General Counsel, Corporationrationrate Secretary of the Company since January 2015 and of Medtronic, Inc. since May 2014. Prior to that, he was Executive Vice President, General Counsel and Corporationrationrate Secretary at Federal National Mortgage Association from October 2012 to May 2014 Senior Vice President and Chief Litigation Counsel at Pfizer, Inc. from January 2009 to September 2012 Partner at Winston Strawn from August 1998 to January 2009 partner at Kirkland Ellis from March 1996 to July 1998 Associate Independent Counsel from October 1994 to March 1996 and Assistant U.S. Attorney in the Northern District of Illinois from February 1986 to September 1994. since 2015.
| Age | 63 |
| Tenure | 9 years |
| Address | 20 On Hatch, Dublin, Ireland, 2 |
| Phone | 353 1 438 1700 |
| Web | https://www.medtronic.com |
Medtronic PLC Management Efficiency
The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Francis Kim | Waters | 51 | |
| Elizabeth Rae | Waters | 60 | |
| Tristan Orpin | Illumina | 49 | |
| Ian King | Waters | 63 | |
| Paula Dowdy | Illumina | N/A | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| Garret Hampton | Illumina | 52 | |
| Andrew Thomson | Thermo Fisher Scientific | 49 | |
| Charles Dadswell | Illumina | 65 | |
| Dominique Grau | Agilent Technologies | 65 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Sanjay Chikarmane | Illumina | N/A | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Kenneth Apicerno | Thermo Fisher Scientific | N/A | |
| Mark Doak | Agilent Technologies | 63 | |
| David Terricciano | Waters | 61 | |
| Karen McGinnis | Illumina | 50 | |
| Omead Ostadan | Illumina | 46 | |
| Robert McMahon | Agilent Technologies | 55 | |
| Alan Malus | Thermo Fisher Scientific | 55 | |
| David Smith | Charles River Laboratories | 58 | |
Management Performance
| Return On Equity | 0.0817 | ||||
| Return On Asset | 0.0423 |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
| Jennifer Kirk, Chief Accounting Officer, Global Controller | ||
| Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Scott Donnelly, Lead Independent Director | ||
| Kenneth Washington, Senior Officer | ||
| Richard Anderson, Lead Independent Director | ||
| Ryan Weispfenning, Vice President - Investor Relations | ||
| Mark Ploof, Senior Services | ||
| Sean Lennon, Chief Officer | ||
| Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group | ||
| Elizabeth Nabel, Independent Director | ||
| Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
| James Lenehan, Independent Director | ||
| John Liddicoat, Executive Vice President and President Americas Region | ||
| Shirley Jackson, Independent Director | ||
| Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
| Preetha Reddy, Independent Director | ||
| Kevin Lofton, Independent Director | ||
| Craig Arnold, Independent Director | ||
| Robert Pozen, Independent Director | ||
| Kendall Powell, Lead Independent Director | ||
| Bryan Hanson, Executive VP and Group President of Minimally Invasive Therapies Group | ||
| Sally Saba, Chief Inclusion and Diversity Officer | ||
| Denise OLeary, Independent Director | ||
| Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
| Brad Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Ivan Fong, General VP | ||
| Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio | ||
| Gary Ellis, CFO and Executive VP | ||
| Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
| Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
| Geoff Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Michael Leavitt, Independent Director | ||
| Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Randall Hogan, Independent Director | ||
| Andrea Goldsmith, Independent Director | ||
| Robert Hoedt, Executive Vice President and President - EMEA Region | ||
| MSc MD, Medical Scientific | ||
| Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0817 | ||||
| Return On Asset | 0.0423 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 122.22 B | ||||
| Shares Outstanding | 1.33 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 85.20 % | ||||
| Number Of Shares Shorted | 12.43 M | ||||
| Price To Earning | 20.44 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.Note that the Medtronic PLC information on this page should be used as a complementary analysis to other Medtronic PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Medtronic Stock analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Medtronic PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medtronic PLC. If investors know Medtronic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medtronic PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.078 | Dividend Share 2.75 | Earnings Share 3.15 | Revenue Per Share 24.298 | Quarterly Revenue Growth 0.047 |
The market value of Medtronic PLC is measured differently than its book value, which is the value of Medtronic that is recorded on the company's balance sheet. Investors also form their own opinion of Medtronic PLC's value that differs from its market value or its book value, called intrinsic value, which is Medtronic PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medtronic PLC's market value can be influenced by many factors that don't directly affect Medtronic PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medtronic PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medtronic PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medtronic PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.